Theratechnologies - THTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $3.25
  • Forecasted Upside: 39.48 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.33
▲ +0.19 (8.88%)

This chart shows the closing price for THTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THTX

Analyst Price Target is $3.25
▲ +39.48% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $3.25, with a high forecast of $3.25 and a low forecast of $3.25. The average price target represents a 39.48% upside from the last price of $2.33.

This chart shows the closing price for THTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Theratechnologies. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2022National Bank FinancialLower TargetC$3.75 ➝ C$3.25Low
2/26/2021Leede Jones GabDowngradeSpeculative Buy ➝ HoldLow
1/31/2021Royal Bank of CanadaReiterated RatingHold$2.00Low
10/16/2020MackieReiterated RatingBuy$4.50High
7/20/2020Royal Bank of CanadaReiterated RatingHold$2.00Low
7/8/2020Echelon Wealth PartnersReiterated RatingBuy$11.00High
2/25/2020MackieReiterated RatingBuy$5.80Low
12/11/2019MackieUpgradeHold ➝ BuyLow
(Data available from 9/26/2017 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/30/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/29/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/29/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/28/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/28/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/26/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Theratechnologies logo
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $2.33
Low: $2.21
High: $2.39

50 Day Range

MA: $2.18
Low: $1.98
High: $2.42

52 Week Range

Now: $2.33
Low: $1.89
High: $4.16

Volume

344,545 shs

Average Volume

64,447 shs

Market Capitalization

$221.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Theratechnologies?

The following Wall Street analysts have issued stock ratings on Theratechnologies in the last twelve months: National Bank Financial.
View the latest analyst ratings for THTX.

What is the current price target for Theratechnologies?

1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 36.6%. National Bank Financial has the highest price target set, predicting THTX will reach $3.25 in the next twelve months. National Bank Financial has the lowest price target set, forecasting a price of $3.25 for Theratechnologies in the next year.
View the latest price targets for THTX.

What is the current consensus analyst rating for Theratechnologies?

Theratechnologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for THTX.

What other companies compete with Theratechnologies?

Other companies that are similar to Theratechnologies include Actinium Pharmaceuticals, Verastem, AC Immune, Kamada and XOMA. Learn More about companies similar to Theratechnologies.

How do I contact Theratechnologies' investor relations team?

Theratechnologies' physical mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company's listed phone number is (514) 336-7800 and its investor relations email address is [email protected] The official website for Theratechnologies is www.theratech.com. Learn More about contacing Theratechnologies investor relations.